Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effectiveness of tipifarnib in patients aged 70
or more with acute myeloid leukemia. Tipifarnib belongs to a class of drugs called Farnesyl
Transferase Inhibitors (FTI). It blocks proteins that make leukemia cells grow.
Phase:
Phase 3
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.